Trial Results Are Significant Breakthrough For ProtoKinetix


VANCOUVER, British Columbia, June 1, 2004 (PRIMEZONE) -- Dr. John Todd, President and CEO of ProtoKinetix (OTCBB:PKTX), states, "Confirmation by the Georges Pompidou Hospital that a clear binding of an antibody to the AFP receptor sites (RECAF(TM)) on certain cancer cells and no binding of the antibody to similar `normal' cells is validation of a unique characteristic about these kinds of cancer cells that sets them apart from healthy cells. This characteristic is a potential `doorway' into these cells that may allow for the entry of a destructive therapeutic agent. A 'doorway' is vital for a therapy to effectively kill only cancer cells."

Todd added, "ProtoKinetix will shortly be announcing the fast track therapeutic development of its hunter killer antibody. This research program will be headed up by Dr. Max Arella in conjunction with the University of Compiegne. In parallel, continuing additional trials on RECAF will be ongoing to test all malignancies. The Company now has evidence that RECAF(TM) exists. Now we will use proven technology as we proceed towards the development of a potential cancer therapy."

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission, including the Company's latest Form 10KSB found at www.se.c.gov under the RJV Networks, Inc. filings.


 On behalf of the Board of Directors,
 Dr. John Todd, President

 Company Office:
 1500-885 West Georgia Street
 Vancouver, BC  V6C 3E8


            

Contact Data